We have carefully chosen our six migraine-proven ingredients
Years of research and experience have been the basis for our choice in the six migraine-proven ingredients. Because we only use natural and proven ingredients our supplement is much better tolerated than migraine medication.
Magnesium (citrate)
90 mg
Choosing magnesium was based on two studies.
- Peikert et al (1996) randomized 81 patients to 600mg elemental magnesium or placebo daily for 12 weeks. Patients treated with magnesium had a significantly higher reduction in attack frequency. The responder rate of a 50% or greater reduction in number of attacks from baseline was 52.8% in the magnesium group and 34.4% in the placebo group in the final month of treatment.
- Pfaffenrath et al (1996) randomized 69 patients to 243 mg elemental magnesium twice daily to placebo for 12 weeks following a 4 week baseline period. The primary outcome was a 50% reduction of migraine duration (in hours) or intensity of migraine at the end of the third month of treatment.The difference was not statistically significant.
B2 (Riboflavin)
400 mg
Choosing vitamin B2 (Riboflavin) was based on two studies.
- Schoenen et al (1998) conducted a trial which compared riboflavin 400 mg daily to placebo. After a one month placebo phase, patients were randomized to riboflavin 400 mg daily or placebo for 12 weeks. The responder rate, defined as the percentage of patients achieving 50% reduction in migraine frequency, was significantly higher in the riboflavin group (56%) versus the placebo.
- Maizels et al (2004) conducted a randomized, double-blind placebo controlled trial in 49 patients over a 3 month period. A compound of daily riboflavin 400 mg with magnesium 300 mg and feverfew
100 mg was compared to a “placebo” of 25 mg of riboflavin. The primary outcome was measured at a 50% or greater reduction of migraines. The difference was not statistically significant.
Coenzyme Q10
150 mg
Choosing coenzyme Q10 was based on one study:
- Sándor et al (2005) conducted a double blind, randomized, placebo-controlled trial in 43 patients with migraine. Patients received either coenzyme Q10 100 mg or placebo for a 3 month period. The primary outcome variable was change of attack frequency in month 4 compared with baseline, and results showed a significant reduction in the coQ10. The 50% responder rate for the coQ10 was significantly higher at 47.6% versus 14.3% in the placebo group. Authors found the coQ10 effect appeared after the first month and was maximal after 3 months of treatment.
Folic acid
1000 mcg
Choosing folic acid was based on three studies:
- Lea et al (2009) reported that vitamin supplementation (2 mg of folic acid, 25 mg of vitamin B6, and 400 mcg of vitamin B12) in MA patients reduced homocysteine levels by 39% when compared to baseline, and the effect was significantly greater than with placebo. Vitamin supplementation also significantly reduced the prevalence of migraine disability from 60% at baseline to 30% after 6 months, whereas no reduction was observed in the placebo group.
- Menon et al (2012) conducted a study on Australian female Caucasians with MA also reported that vitamin (B6, B9 (folic acid), and B12) supplementation not only significantly reduced homocysteine levels but also reduced the severity of migraine headache and disability among migraineurs when compared to placebo.
- Menon et al (2016) conducted a 6 month randomised, double blinded placebo controlled trial of daily vitamin supplementation containing 1 mg of folic acid, 25 mg of Vitamin B6 and Vitamin B12, on reduction of homocysteine and the occurrence of migraine in 300 female patients diagnosed with migraine with aura. They found 1 mg of folic acid in combination with vitamin B6 and B12 is less effective in reducing migraine associated symptoms compared to the previously tested dosage of 2 mg folic acid in combination with 25 mg of vitamin B6 and 400 μg of vitamin B12.
B12
400 mcg
Choosing B12 was based on three studies:
- Lea et al (2009) reported that vitamin supplementation (2 mg of folic acid, 25 mg of vitamin B6, and 400 mcg of vitamin B12) in MA patients reduced homocysteine levels by 39% when compared to baseline, and the effect was significantly greater than with placebo. Vitamin supplementation also significantly reduced the prevalence of migraine disability from 60% at baseline to 30% after 6 months, whereas no reduction was observed in the placebo group.
- Menon et al (2012) conducted a study on Australian female Caucasians with MA also reported that vitamin (B6, B9 (folic acid), and B12) supplementation not only significantly reduced homocysteine levels but also reduced the severity of migraine headache and disability among migraineurs when compared to placebo.
- Van der Kuy et al (2002) conducted an open trial with 20 patients. A 1 month baseline was followed by 3 months of 1 mg B12 daily. A reduction in migraine attack frequency of +50% was seen in 10 of 19 patients, which corresponds to 53% of the patients (responders). A reduction +30% was noted in 63% of the patients.
B6
20 mg
Choosing B6 was based on two studies:
- Lea et al (2009) reported that vitamin supplementation (2 mg of folic acid, 25 mg of vitamin B6, and 400 mcg of vitamin B12) in MA patients reduced homocysteine levels by 39% when compared to baseline, and the effect was significantly greater than with placebo. Vitamin supplementation also significantly reduced the prevalence of migraine disability from 60% at baseline to 30% after 6 months, whereas no reduction was observed in the placebo group.
- Menon et al (2012) conducted a study on Australian female Caucasians with MA also reported that vitamin (B6, B9 (folic acid), and B12) supplementation not only significantly reduced homocysteine levels but also reduced the severity of migraine headache and disability among migraineurs when compared to placebo.